Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia

Clinical Cancer Research

Volumn 8, Issue 7, 2002, Pages 2134-2141

  Giles, Francis J ^a,b   Cortes, Jorge E ^a   Thomas, Deborah A ^a   Garcia Manero, Guillermo ^a   Faderl, Stephan ^a   Jeha, Sima ^a   De Jager, Robert L ^a   Kantarjian, Hagop M ^a  

^a Daiichi Pharmaceutical Corporation   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DNA TOPOISOMERASE; DRUG DERIVATIVE; ENZYME INHIBITOR; EXATECAN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; IRINOTECAN;

ACUTE DISEASE; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG ANTAGONISM; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; METABOLISM; MIDDLE AGED; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; PHASE 1 CLINICAL TRIAL; SALVAGE THERAPY; STOMATITIS; ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; COMBINED IMMUNODEFICIENCY; COMPARTMENT MODEL; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG MECHANISM; LEUKEMIA; MAXIMUM TOLERATED DOSE; PRIORITY JOURNAL; RELAPSE; SCHOOL CHILD; STATISTICAL MODEL; TOXICITY TESTING;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; DNA TOPOISOMERASES, TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; SALVAGE THERAPY; STOMATITIS; HUMAN; MIDDLE AGE;

EID: 0035992308     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Plant antitumor agents. 23. Synthesis and antileukemic activity of camptothecin analogues
2. Plant antitumor agents. 22. Isolation of 11-hydroxycamptothecin from Camptotheca acuminata Decne: Total synthesis and biological activity
3. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I
4. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts
5. DNA topoisomerase poisons as antitumor drugs
6. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer
7. Treatment of malignant melanoma with camptothecin (NSC-100880)
8. Topoisomerase I inhibitors: Topotecan and irenotecan
9. Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia
10. Phase I study of topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia
11. New chemotherapeutic agents in acute myeloid leukemia
12. New developments in the treatment of acute myeloid leukemia: Focus on topotecan
13. New agents for the treatment of acute myelogenous leukemia: Focus on topotecan and retinoids
14. Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia
15. Topotecan in the treatment of hematologic malignancies
16. Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia
17. A phase I and pharmacological study of topotecan infused over 30 minutes for five days in patients with refractory acute leukemia
18. Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia
19. Results of topotecan-based combination therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia
20. Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia
21. The current status of camptothecin analogues as antitumor agents
22. An overview of topoisomerase I-targeting agents
23. DNA topoisomerase I poisons
24. The clinical development of 9-aminocamptothecin
25. A new water-soluble camptothecin derivative. DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo
26. Characterization of a human small-cell lung cancer cell line resistant to a new water-soluble camptothecin derivative. DX-8951f
27. Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice
28. DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant
29. Topoisomerase I inhibitors: Review and update
30. A risk-benefit assessment of irinotecan in solid tumours
31. Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice
32. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SKandF 104864), a new camptothecin analogue
33. Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells
34. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo
35. In vitro and in vivo effects of clinically important camptothecin analogues on multidrug-resistant cells
36. In vivo activity of the topoisomerase 1 inhibitor DX-8951f against human acute myeloid leukemia engrafted in SCID mice
37. The topoisomerase I inhibitor DX-8951f is active in a severe combined immunodeficient mouse model of human acute myelogenous leukemia
38. Schedule dependance and CNS activity of a novel topoisomerase 1 inhibitor DX-8951f in a human acute myeloid leukemia SCID mice model
39. DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: A Phase I and pharmacokinetic study in patients with advanced solid malignancies
40. Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-minute infusion every 3 weeks in patients with advanced cancer
41. Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): A novel camptothecin analog
42. Phase I and pharmacological study of a new camptothecin derivative, exatecan mesylate (DX-8951f), infused over 30 minutes every three weeks
43. Sensitive high-performance liquid chromatographic method for the determination of the lactone form and the lactone plus hydroxy-acid forms of the new camptothecin derivative DX-8951 in human plasma using fluorescence detection
44. Validation study of assay method for DX-8951 and its metabolite in human plasma and urine by high-performance liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry
45. Extended least squares (ELS) for pharmacokinetic models
46. Statistical moments in pharmacokinetics
47. Anticancer activity of DX-8951f, a water soluble camptothecin against human tumor specimens taken directly from adult and pediatric patients
48. Comparison of DX-8951f clinical and pre-clinical toxicities
49. Activity of oral and intravenous 9-aminocamptothecin in SCID mice engrafted with human leukemia
50. The topoisomerase 1 inhibitor. NX211 demonstrates significant in vivo activity against human acute myeloid leukemia engrafted in SCID mice
51. Phase I and pharmacokinetic (PK) study of DX-8951f, a novel hexacyclic camptothecin (CPT) analog, on a 30 minute infusion daily for 5 days every 3 week schedule
52. Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks
53. Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts
54. High-dose chemotherapy in high-risk myelodysplastic syndrome: Covariate- adjusted comparison of five regimens
55. Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation in patients with refractory or relapsed acute leukemia
56. 9-Nitro-camptothecin delays growth of U-937 leukemia tumors in nude mice and is cytotoxic or cytostatic for human myelomonocytic leukemia lines in vitro
57. Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using nonsubstrate drugs or the BCRP inhibitor GF120918